RxDoctor Payments DataLook up a doctor →

Tracey Hoffman, NP

Family · Louisville, KYNPI 1306148671

Payments from drug & device makers

$19,196in general payments, 2019–2025

Across 530 payments — averaging $36.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$7K
  • AstraZeneca$917
  • Amgen$877
  • Incyte Corporation$759
  • E.r. Squibb & Sons, L.L.C.$675
  • Seagen Inc.$647
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$2,09311%
  • Speaking & faculty fees$3,48518%
  • Travel & lodging$7214%
  • Food & beverage$12,46865%
  • Education$4302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.41$7,419
AstraZeneca22$917
Amgen34$877
Incyte Corporation35$759
E.r. Squibb & Sons, L.L.C.30$675
Seagen Inc.27$647
Merck30$561
Gilead(2 entities)15$548
Novartis36$547
Johnson & Johnson26$496
Rigel Pharmaceuticals, Inc.12$431
Pfizer21$415
Sanofi13$348
Coherus Oncology, Inc.14$343
Lilly USA, LLC12$272
Daiichi Sankyo Inc.17$269
Stemline Therapeutics Inc.3$259
Takeda Pharmaceuticals U.S.A., Inc.6$253
Bayer10$236
Beigene USA, Inc.6$175
AbbVie7$175
Novocure Inc.3$165
Exelixis Inc.1$122
Iovance Biotherapeutics, Inc.1$114
Sobi, Inc2$111
Mirati Therapeutics, Inc.2$110
Regeneron Healthcare Solutions, Inc.5$108
Blue Earth Diagnostics5$105
Blueprint Medicines Corporation5$104
GSK5$101
Agios Pharmaceuticals, Inc.1$100
Bristol Myers Squibb6$99
Array Biopharma Inc7$99
Boehringer Ingelheim5$93
Pharmacyclics LLC, An Abbvie Company6$93
Morphosys, US Inc.5$81
Genentech USA, Inc.4$78
Dova Pharmaceuticals4$73
Karyopharm Therapeutics Inc.4$71
Kyowa Kirin, Inc.4$65
Sumitomo Pharma America, Inc.3$60
ADC Therapeutics America, Inc.4$59
Alnylam Pharmaceuticals Inc.3$58
Tersera Therapeutics LLC3$55
EMD Serono, Inc.2$50
Puma Biotechnology, Inc.3$46
Cumberland Pharmaceuticals, Inc.2$37
Ipsen Biopharmaceuticals, Inc2$37
Pharmaessentia USA Corporation2$36
Emmaus Medical, Inc.2$33
Taiho Oncology, Inc.2$31
Progenics Pharmaceuticals, Inc.1$24
Servier Pharmaceuticals LLC1$22
Adaptive Biotechnologies Corporation1$21
Ferring Pharmaceuticals Inc.1$20
G1 Therapeutics, Inc.1$19
Foundation Medicine, Inc.1$17
Springworks Therapeutics, Inc.1$16
Recordati_rare_diseases_inc.1$15
Global Blood Therapeutics, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,196 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$4,619
Medicare patients
64
Services billed
89

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl17$120

Paid to pharmacies, not to this prescriber.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →